Mallinckrodt Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MALLINCKRODT, and what generic alternatives to MALLINCKRODT drugs are available?
MALLINCKRODT has forty-six approved drugs.
There are thirty-five US patents protecting MALLINCKRODT drugs.
There are one hundred and sixty-five patent family members on MALLINCKRODT drugs in twenty-three countries and seventy-eight supplementary protection certificates in eight countries.
Summary for Mallinckrodt
| International Patents: | 165 |
| US Patents: | 35 |
| Tradenames: | 40 |
| Ingredients: | 29 |
| NDAs: | 46 |
| Patent Litigation for Mallinckrodt: | See patent lawsuits for Mallinckrodt |
| PTAB Cases with Mallinckrodt as patent owner: | See PTAB cases with Mallinckrodt as patent owner |
Drugs and US Patents for Mallinckrodt
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mallinckrodt Ireland | TERLIVAZ | terlipressin acetate | POWDER;INTRAVENOUS | 022231-001 | Sep 14, 2022 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Mallinckrodt | MD-60 | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 087074-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Mallinckrodt Hosp | OFIRMEV | acetaminophen | SOLUTION;INTRAVENOUS | 022450-001 | Nov 2, 2010 | DISCN | Yes | No | 10,383,834 | ⤷ Subscribe | ⤷ Subscribe | ||||
| Mallinckrodt Inc | XARTEMIS XR | acetaminophen; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204031-001 | Mar 11, 2014 | DISCN | Yes | No | 8,992,975 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-003 | Dec 23, 1999 | AA | RX | Yes | Yes | 11,931,377*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Mallinckrodt | TECHNECOLL | technetium tc-99m sulfur colloid kit | SOLUTION;INJECTION, ORAL | 017059-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mallinckrodt
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-002 | Dec 23, 1999 | 5,485,827*PED | ⤷ Subscribe |
| Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-003 | Dec 23, 1999 | 5,558,083*PED | ⤷ Subscribe |
| Mallinckrodt Hosp | INOMAX | nitric oxide | GAS;INHALATION | 020845-003 | Dec 23, 1999 | 6,125,846*PED | ⤷ Subscribe |
| Mallinckrodt Hosp | OFIRMEV | acetaminophen | SOLUTION;INTRAVENOUS | 022450-001 | Nov 2, 2010 | 6,028,222*PED | ⤷ Subscribe |
| Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | 5,036,102 | ⤷ Subscribe |
| Mallinckrodt Hosp | UVADEX | methoxsalen | INJECTABLE;INJECTION | 020969-001 | Feb 25, 1999 | 4,999,375 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MALLINCKRODT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | for Inhalation | 100 ppm and 800 ppm | ➤ Subscribe | 2014-05-20 |
| ➤ Subscribe | Extended-release Tablets | 7.5 mg/325 mg | ➤ Subscribe | 2014-04-03 |
| ➤ Subscribe | Injection | 1000 mg/100 mL (10 mg/mL) | ➤ Subscribe | 2011-04-07 |
Premature patent expirations for MALLINCKRODT
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| ⤷ Subscribe | ⤷ Subscribe |
International Patents for Mallinckrodt Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 4351619 | ⤷ Subscribe |
| China | 106055863 | ⤷ Subscribe |
| Japan | 2005507000 | ⤷ Subscribe |
| Japan | 2022101594 | ⤷ Subscribe |
| Japan | 7395641 | ⤷ Subscribe |
| Japan | 7024013 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mallinckrodt Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0786264 | SPC/GB08/019 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: NITRIC OXIDE (NO); REGISTERED: UK EU/1/01/194/001 20010801 |
| 2203431 | 92666 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119 |
| 0186405 | SPC/GB00/021 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316 |
| 1912999 | 14C0076 | France | ⤷ Subscribe | PRODUCT NAME: SIMEPREVIR OU L'UN DE SES SELS, INCLUANT LE SEL DE SODIUM DE SIMEPREVIR; REGISTRATION NO/DATE: EU/1/14/924 20140516 |
| 2932970 | 1890039-9 | Sweden | ⤷ Subscribe | PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518 |
| 1856135 | CA 2020 00018 | Denmark | ⤷ Subscribe | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REG. NO/DATE: EU/1/19/1405 20200113 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
